A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-29 and is reviewed periodically as new material appears.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
The progressive miniaturization of low-voltage lighting technology, such as LEDs and OLEDs, suitable to incorporate into low-thickness materials has fostered experimentation in combining light sources and wall covering surfaces for interior walls in the form of LED wallpaper.
A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7) is an enzyme that in humans is encoded by the ADAMTS7 gene on chromosome 15. It is ubiquitously expressed in many tissues and cell types. This enzyme was historically reported to catalyze the degradation of cartilage oligomeric matrix protein (COMP), though subsequent studies using purified proteins and unbiased mass spectrometry found that ADAMTS7 does not cleave COMP. ADAMTS7 has been associated with cancer and arthritis in multiple tissue types. The ADAMTS7 gene is a well-established genetic susceptibility locus for coronary artery disease.
== Sources == Forbes (2014). "Alexander Rich". Profiles. Forbes. Archived from the original on 15 March 2014. Retrieved 15 March 2014. Gen. Eng. Biotechnol. News (February 15, 2014). "BioMarin Nabs Repligen's HDACi Compound Library". News: Discovery & Development. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. p. 14. International New York Times (2014). "Repligen Corporation". Business Day. International New York Times. Company Information. Archived from the original on 15 March 2014. Retrieved 15 March 2014. Motley Fool (2014). "Repligen Corp Key Executives RGEN". The Motley Fool. Archived from the original on 15 March 2014. Retrieved 15 March 2014. "Repligen Corporation, Form 10-K, 2013", SEC Documents, Form 10-K, Repligen, 2014-03-14, Commission File Number 000-14656, retrieved 2026-05-15{{citation}}: CS1 maint: year (link) Street Insider (19 September 2011). "Repligen (RGEN) Replaces Board Member Alex Rich with Alfred Goldberg". Street Insider. Archived from the original on 15 March 2014. Retrieved 15 March 2014.
Sources: en.wikipedia.org
== Diagnostic use == S100B is secreted by astrocytes or can spill from injured cells and enter the extracellular space or bloodstream. Serum levels of S100B increase in patients during the acute phase of brain damage. Over the last decade, S100B has emerged as a candidate peripheral biomarker of blood–brain barrier (BBB) permeability and CNS injury. Elevated S100B levels accurately reflect the presence of neuropathological conditions including traumatic head injury or neurodegenerative diseases. Normal S100B levels reliably exclude major CNS pathology. Its potential clinical use in the therapeutic decision making process is substantiated by a vast body of literature validating variations in serum 100B levels with standard modalities for prognosticating the extent of CNS damage: alterations in neuroimaging, cerebrospinal pressure, and other brain molecular markers (neuron specific enolase and glial fibrillary acidic protein). However, more importantly, S100B levels have been reported to rise prior to any detectable changes in intracerebral pressure, neuroimaging, and neurological examination findings. Thus, the major advantage of using S100B is that elevations in serum or CSF levels provide a sensitive measure for determining CNS injury at the molecular level before gross changes develop, enabling timely delivery of crucial medical intervention before irreversible damage occurs. S100B serum levels are elevated before seizures suggesting that BBB leakage may be an early event in seizure development.
Mendelevium is a synthetic chemical element; it has symbol Md (formerly Mv) and atomic number 101. A metallic radioactive transuranium element in the actinide series, it is the first element by atomic number that currently cannot be produced in macroscopic quantities by neutron bombardment of lighter elements. It is the thirteenth actinide, the ninth transuranic element, and the first transfermium; it is named after Dmitri Mendeleev, the father of the periodic table. Like all the transfermiums, it can only be produced in particle accelerators by bombarding lighter elements with charged particles. The element was first produced in 1955 by bombarding einsteinium with alpha particles, the method still used today. Using commonly-available microgram quantities of einsteinium-253, over a million mendelevium atoms may be made each hour. The chemistry of mendelevium is typical for the late actinides, with a dominant +3 oxidation state but also a +2 oxidation state accessible in solution. All known isotopes of mendelevium have short half-lives; there are currently no uses for it outside basic scientific research, and only small amounts are produced.
Lately Intelligence Officer, Home Office. For services to Border Security. The Reverend Christopher Richard Colledge. For services to the community in Bournemouth, Dorset. Alan Collier. Director, Procurement and Sustainability, Norfolk County Council. For services to Local Government. Dr. Michael Patrick Collins. Lately Science Lead on EU and International Science Partnerships, Department for Environment, Food and Rural Affairs. For services to International Science Policy. Denise Cooke. Administrative Officer, Maritime and Coastguard Agency. For Public Service. Laura Coryton. Tampon Tax Campaigner, Author and Co-Founder, Sex Ed Matters. For services to Charitable Campaigning. Margaret Irene Cosin. Lately Member, Dover District Council. For Political and Public Service. Stuart Samuel Cossar. Investigation Manager, Police Service of Scotland. For services to the Investigation and to the Bereaved Families of the Lockerbie Air Disaster. Anne Marie Coulter. Volunteer, Summerhill Community Centre. For services to the community in Dumfries. Samuel Robert John Cousley. Head of Seafarers, Department for Transport. For services to Seafarers. Professor Rachel Elizabeth Cowgill. Professor of Music, University of York. For services to Culture, to Education and to the Arts. John Hubert Cox. Chair, Joseph Cox Charity. For services to Homeless People in Manchester. Maureen Joan Cox. For charitable services in the London Borough of Hackney. Vanessa Sara Crocker. Co-Founder, Spread a Smile. For services to Seriously and Terminally Ill Children and their Families. Daniel Steven Paul Croft.
Sources: en.wikipedia.org
=== Other party leaders in parliament === Labour – Chris Hipkins (Leader of the Opposition) Green – Marama Davidson and Chlöe Swarbrick ACT – David Seymour NZ First – Winston Peters Te Pāti Māori – Rawiri Waititi and Debbie Ngarewa-Packer
=== Method Development === Method development of chiral chromatography is still done by screening of columns from the various classes of chiral columns. While chiral separation mechanisms are understandable in certain scenarios, and the retention characteristics of analytes within the chromatographic columns can occasionally be elucidated, the precise combination of chiral stationary phases (CSPs) and mobile-phase compositions that required to effectively resolve a specific enantiomeric pair often remains elusive. The chemistry of CSP ligands significantly influences the creation of in-situ diastereomeric complexes upon the stationary phase surface. However, other method's conditions, such as mobile-phase solvents, their composition, mobile phase additives and column temperature can play equally critical roles. The final resolution of the enantiomers is the outcome of combination of intermolecular forces, and even a subtle change in them can determine the success or failure of separation. This complexity prevents from establishing routine method-development protocols that are universally applicable to a diverse range of enantiomers. In fact, sometimes the outcome of previous unsuccessful experiments do not provide any clue for the subsequent steps.
== Data produced by structural alignment == The minimum information produced from a successful structural alignment is a set of residues that are considered equivalent between the structures. This set of equivalences is then typically used to superpose the three-dimensional coordinates for each input structure. (Note that one input element may be fixed as a reference and therefore its superposed coordinates do not change.) The fitted structures can be used to calculate mutual RMSD values, as well as other more sophisticated measures of structural similarity such as the global distance test (GDT, the metric used in CASP). The structural alignment also implies a corresponding one-dimensional sequence alignment from which a sequence identity, or the percentage of residues that are identical between the input structures, can be calculated as a measure of how closely the two sequences are related.
Mass spectrometer is in fact hyphenation between the separative instrument and a mass spectrometry instrument to get information on the molecular weight or atomic weight of the solute. In the advanced mass spectrometry technologies there is information on solutes structure and even chemical properties. The hyphenation between ultra high performance chromatography with high resolution mass spectrometers revolutionalized entire new scientific fields of research and application, such as toxicology, proteomics, lipidomics, genomics, metabolomics and metabonomics.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.